CSCO 2016:骨与软组织肉瘤外科治疗进展

2016-09-26 MedSci MedSci原创

2016年9月22日-24日,第19届全国临床肿瘤学大会暨2016年CSCO学术年会在福建厦门国际会议中心举行。24日,在大会现场,北京积水潭医院骨肿瘤科张清教授作了题为《骨与软组织肉瘤外科治疗进展》的精彩报告,讲述骨与软组织肉瘤这种罕见肿瘤在外科治疗的进展的同时,对推动骨与软组织肿瘤外科治疗进步的基石做出了详细的介绍。现梅斯医学小编对其内容进行了以下整理。 骨与软组织肉瘤概况骨与软组织

2016年9月22日-24日,第19届全国临床肿瘤学大会暨2016年CSCO学术年会在福建厦门国际会议中心举行。



24日,在大会现场,北京积水潭医院骨肿瘤科张清教授作了题为《骨与软组织肉瘤外科治疗进展》的精彩报告,讲述骨与软组织肉瘤这种罕见肿瘤在外科治疗的进展的同时,对推动骨与软组织肿瘤外科治疗进步的基石做出了详细的介绍。现梅斯医学小编对其内容进行了以下整理。
 
骨与软组织肉瘤概况

骨与软组织肉瘤属于罕见性肿瘤,占全部恶性肿瘤的1-2%,其中骨肉瘤在10万肿瘤患者中占1-2万,而软组织肉瘤占1.28-1.72万,软组织肉瘤占成人全部恶性肿瘤0.73-0.81%,占15岁以下儿童全部恶性肿瘤6.5%。

发病年龄:

骨与软组织肉瘤可发生在任何年龄,其中骨肉瘤以青少年为主。在性别方面,患者男性略多于女性。

发病部位:

骨肉瘤在干骺端,股骨远端、胫骨近段、肱骨近段。软组织肉瘤则可发生在任何部位,50-60%在肢体(15-20%位于上肢,35-40%位于下肢),20-25%位于腹膜后或腹腔,15-20%位于躯干的胸壁或背部,5%位于头颈部,最终造成患者肢体畸形和残疾。

转移:

骨的恶性肿瘤区域转移中淋巴转移很少,远隔转移以肺为主;软组织肉瘤则以肺转移为主,区域转移<4%,部分>10%(透明细胞肉瘤27.5%,上皮羊肉瘤16.7%,血管肉瘤13.5%,胚胎型横纹肌肉瘤13.6%),远隔转移以肺为主,占50%。

治疗:

骨与软组织肉瘤的治疗方式主要以外科治疗为主,内科治疗为辅(化疗是重要的综合治疗手段,此外还有靶向治疗,免疫治疗),并结合放疗和中医中药治疗。

需要注意的是,骨与软组织肉瘤肿瘤外科治疗离不开各种相关学科及技术的发展,那么,推动其进步的基石有哪些呢?

1、影像学的发展,如X片、CT、MRI、ECT及PETCT
常规的CT检查为保留肢体提供精细的信,有助于分析肿瘤所在解剖部位,可以预期肿瘤切除边界和显示重要的神经血管结构,有利于术前规划手术入路及肿瘤外科切除边界;而MRI检查作为一种非侵入性肿瘤影像的解剖细节,多种序列影像能分辨正常和异常组织,有助于在复杂解剖区域,如骨盆、肩关节等,实行肿瘤切除保留肢体做术前计划;胸部CT和ECT检查在肿瘤分期是必不可少的,胸部CT检查是否存在肿瘤分期远隔肺转移,ECT检查多中心病灶、跳跃病灶和卫星病灶。

2、肌肉骨骼系统肿瘤外科分期的建立

骨与软组织肉瘤分期类型有四种,IIA(G2T1M0)表明骨内、未转移;IIB(G2T2M0)表明已累及骨外软组织,未转移;IIIA(G2T1M1)表明骨内、已有区域或远隔转移;IIIB(G2T2M1)表明已累及骨外软组织,已有区域或远隔转移。
3、综合治疗的发展

4、外科重建技术不断提高

张清教授简介:

男,北京积水潭医院骨肿瘤科主任医师,副教授,骨肿瘤科副主任,医学硕士,1989年毕业于北京医科大学.国际保肢学会会员;中国抗癌协会临床肿瘤协作中心会员,中国抗癌协会肉瘤专业委员会委员、秘书,化疗学组秘书;北京市骨科学会骨肿瘤学组副组长。专业特长:骨肉瘤的诊断、化疗、保肢治疗恶性骨肿瘤的保肢治疗及化疗、骨转移癌的外科治疗及止痛治疗。

张清教授擅长于骨肿瘤的外科治疗、软组织肿瘤的外科治疗、骨肉瘤的诊断、化疗、保肢治疗恶性骨肿瘤的保肢治疗及化疗、骨巨细胞瘤的治疗,恶性骨肿留保留关节外科治疗、良性骨肿瘤的微创手术、骨肿瘤的计算机辅助导航外科手术、骨转移癌的外科治疗及止痛治疗。


更多关于CSCO 2016的最新报道,请点击活动:CSCO 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1420381, encodeId=145f1420381f0, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Wed Sep 28 05:33:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135600, encodeId=cb231356009f, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:31 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135599, encodeId=1a601355998c, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:15 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135571, encodeId=4c781355e19a, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:57:58 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-28 qilu_qi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1420381, encodeId=145f1420381f0, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Wed Sep 28 05:33:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135600, encodeId=cb231356009f, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:31 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135599, encodeId=1a601355998c, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:15 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135571, encodeId=4c781355e19a, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:57:58 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-26 知难而进

    继续关注!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1420381, encodeId=145f1420381f0, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Wed Sep 28 05:33:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135600, encodeId=cb231356009f, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:31 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135599, encodeId=1a601355998c, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:15 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135571, encodeId=4c781355e19a, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:57:58 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-26 知难而进

    谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1420381, encodeId=145f1420381f0, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Wed Sep 28 05:33:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135600, encodeId=cb231356009f, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:31 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135599, encodeId=1a601355998c, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 21:21:15 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135571, encodeId=4c781355e19a, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:57:58 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-26 1e0a2178m68(暂无匿称)

    非常值得学习,要重视

    0